Epobiokrin solution for injections is appointed at the following indications:

• Treatment of the symptomatic anemia connected with chronic kidney disease
  • treatment of the anemia connected with chronic kidney disease at children and adults on a hemodialysis and adult patients on peritoneal dialysis;
  • treatment of the heavy anemia of renal origin which is followed by clinical symptoms at adult patients with a renal failure which did not pass a hemodialysis yet.
• Treatment of anemia and decrease in volume of necessary hemotransfusions at adult patients who receive chemotherapy because of not myelome tumor, a malignant lymphoma or a multiple myeloma and at whom the risk of transfusion estimated on the general condition of the patient is increased (including a condition of a cardiovascular system, the existing anemia prior to the beginning of chemotherapy).
• Epobiokrin can be applied within the predeposit program before considerable surgical interventions to patients with moderate manifestations of anemia (level of hemoglobin of 10-13 g/dl (6.2-8.1 mmol/l), lack of the zhelezodefitsit) to simplification of selection of autologous blood and reduction of the risk connected with use of allogenic hemotransfusions if the expected need for blood for transfusion exceeds quantity which can be received by method of autologous collecting without use of an epoetin an alpha.
• Epobiokrin is applied to adult patients with easy and average degree of anemia (hemoglobin within 10–13 g/l, in the absence of the zhelezodefitsit) before carrying out extensive orthopedic operations from the loss of blood (900 - 1800 ml of blood) expected by average degree to reduction of need for allogenic hemotransfusions and simplification of system recovery of an erythrogenesis.

Structure

Active ingredient: Epoetin alfa;

1 ml of solution recombinant erythropoietin of the person 1000 ME either 2000 ME, or 4000 ME, or 10000 ME;

Excipients: albumine of the person; sodium citrate; sodium chloride; citric acid monohydrate; water for injections.

Contraindication

• Hypersensitivity to medicament components.
• Development of a true erythrocyte aplasia owing to treatment epoetiny an alpha (see. "Features of use").
• Uncontrollable hypertensia.
• Contraindication, connected with the program of selection of autologous blood at the patients receiving epoetin an alpha.
• Heavy coronary, periferichno-arterial, carotid or cerebral vascular diseases and also recently had myocardial infarction or a stroke at the patients who are subject to elective orthopedic surgery, but not taking part in the program of selection of autologous blood. Impossibility of use of adequate antitrombotichesky prevention to surgical patients.

Route of administration

Epoetin an alpha can be applied by subcutaneous and intravenous injections.

As well as at use of any parenteral medicines, medicament epoetin an alpha before use is checked for lack of visible foreign particles and discoloration of solution.

All other causes of anemia (deficiency of iron, folic acid, B12 vitamin, poisoning with aluminum, infections or inflammation, a loss of blood, hemolysis or fibrosis of marrow of any etiology) needs to be defined and cured prior to therapy epoetiny an alpha and before the decision to increase a dosage. For achievement of the optimum response to treatment epoetiny an alpha it is necessary to provide the sufficient level of intake of iron in an organism and, if necessary, in addition to appoint iron administration of drugs.

Intravenous administration.

Epoetin an alpha is applied by an injection lasting from 1 to 5 minutes, depending on a medicament dose. To the patients who are on a hemodialysis, it is possible to enter a bolyusny injection directly into procedure time through venous port suitable for this purpose in the line of dialysis. Also the medicament can be administered after the end of a procedure of a hemodialysis through a catheter fistula with the subsequent introduction 10 ml of isotonic sodium of chloride for washing of a system and appropriate distribution of medicament in a blood-groove.

Slow introduction is applied mainly to patients with manifestations of symptoms of cold.

Epoetin an alpha cannot be applied in the form of intravenous infusions or to mix with other drugs.

Feature of use

Pregnant

Drug Epobiokrin should be used only in case the potential advantage of therapy exceeds potential risk for a fruit.

by

for treatment of the anemia connected with chronic kidney disease at children aged from 1 month up to 18 years which are on dialysis. Safety and efficiency of use of medicament for children aged up to 1 month is not established.

Overdose

Drug has broad therapeutic effect. At overdose epoetiny an alpha there are effects reflecting the highest extent of manifestation of pharmacological effect of hormone. At exclusively high levels of hemoglobin performing phlebotomy is possible. In case of need perform symptomatic therapy.

Side effects

Most frequent undesirable side reaction at treatment epoetiny an alpha at oncological patients and patients with chronic kidney disease dose-dependent increase in arterial blood pressure or deterioration in the existing hypertensia. Control of arterial blood pressure needs to be carried out from an initiation of treatment. Other frequent side reactions is the deep vein thrombosis, a pulmonary embolism, spasms, diarrhea, nausea, a headache, a grippopodobny state, a pyrexia, rash and vomiting.

Interaction

Is not present any data which would indicate that epoetiny the alpha renders treatment influences metabolism of other drugs.

Medicines reducing an erythrogenesis can reduce the response to treatment epoetiny an alpha.

At patients with a metastatic breast cancer the hypodermic introduction of an epoetin an alpha in a dose of 40000 PIECES/ml along with trastuzumab in a dose 6mg/kg did not influence trastuzumab pharmacokinetics.

to Store

in original packing for protection against effect of light at a temperature from 2 to 8 °C. Not to freeze. Not to stir up.

to Store

out of children's reach.

Expiration date - 2 years.